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Abstract 
Background. The mineralocorticoid pathway is involved in cardiac arrhythmias associated 
with heart failure (HF) through yet incompletely understood mechanisms. Defective regulation of 
the cardiac ryanodine receptor (RyR) is an important cause in the initiation of arrhythmias. Here, 
we examined whether the aldosterone pathway might modulate RyR function. 
Methods and results. Using whole-cell patch-clamp, we observed an increase in the 
occurrence of delayed after-depolarizations during action potential recordings in isolated adult rat 
ventricular myocytes exposed 48 hours to 100 nmol/L aldosterone, in freshly isolated myocytes 
from transgenic mice with human mineralocorticoid receptor expression in the heart and in wild-
type littermates treated with aldosterone. Sarcoplasmic reticulum Ca
2+
 load and RyR expression 
were not altered, however, RyR activity, visualized in situ by confocal microscopy, was increased 
in all these cells, as evidenced by an increased occurrence and redistribution to long-lasting and 
broader populations of spontaneous Ca
2+
 sparks. These changes were associated with down-
regulation of FK506-binding proteins (FKBP12 and 12.6), regulatory proteins of the RyR 
macromolecular complex. 
Conclusions. We suggest that, in addition to modulation of Ca
2+
 influx, over stimulation of 
the cardiac mineralocorticoid pathway in the heart might be a major upstream factor for aberrant 
Ca
2+
 release during diastole, contributing to cardiac arrhythmia in HF. 
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Introduction 
During the past decade, research has focused on the actions of aldosterone in target organs 
beyond the kidney, expanding the role of the aldosterone pathway in cardiovascular pathogenesis
1
. 
Indeed, mineralocorticoid receptors (MR), which mainly underlie aldosterone action, have been 
detected in a range of non-renal tissues including the brain, blood vessels and the heart
2
, suggesting 
a broader pattern of biological activity for aldosterone than previously anticipated. The pivotal role 
of aldosterone, causing sodium retention with expansion of the extracellular volume, resulting in 
deterioration of hemodynamic responsiveness and a fall in cardiac output, has long been recognized 
in heart failure (HF)
3,4
. In addition, accumulating experimental and clinical evidence suggests that 
aldosterone has direct adverse cardiac effects independent of its effects on blood pressure, 
especially an increased risk of arrhythmic death
3,4
. Interestingly, major clinical trials involving MR 
antagonists have shown significant benefits on risk of cardiovascular events, in particular sudden 
death in HF
5,6
. A pertinent question is, therefore, how activation of cardiac MR participates in life-
threatening arrhythmias? 
Most fatal arrhythmias in experimental HF initiate by nonreentrant mechanisms arising from 
abnormal ventricular automaticity or triggered
 
activity
7,8
. The latter consists of either early after-
depolarizations (EADs) occurring in the plateau phase of the action potential (AP) or delayed after-
depolarizations (DADs) occurring at repolarized
 
membrane potentials
9
. EADs typically occur in the 
setting of prolonged repolarization due to alterations in ionic currents and to reactivation of Ca
2+
 
current (ICa). DADs are caused by membrane depolarization initiated by spontaneous Ca
2+
 release 
from the sarcoplasmic reticulum (SR) through the ryanodine receptor (RyR). We have accumulated 
evidence, both ex and in vivo, that the modulation of Ca
2+
 influx is a central factor in the cardiac 
action of aldosterone pathway
10-14
 and might be involved in EAD-related fatal ventricular 
tachyarrhythmia
14
. Moreover, enhanced diastolic leak of Ca
2+
 via the RyRs generates DADs and is 
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a fundamental mechanism underlying several genetic or acquired arrhythmias
15,16
. Therefore, we 
tested here whether the activation of aldosterone pathway modulates diastolic RyR activity in heart. 
 
Methods 
All experiments were carried out according to European Union Council Directives 
(86/609/EEC) for the care of laboratory animals. The authors had full access to and take full 
responsibility for the integrity of the data. All authors have read and agree to the manuscript as 
written. 
A detailed Methods section can be found in the online Supplemental Material. 
Cell isolation and incubation 
Isolated ventricular myocytes from adult male Wistar rats (250-350 g) were incubated for 48 
hours, with or without 100-nmol/L D-Aldosterone (Sigma). In some experiments, 10-mol/L 
RU28318 was added to aldosterone
10,11
. 
hMR transgenic mice and in vivo aldosterone exposure 
Cardiac-specific expression of human MR (hMR) was obtained by crossing a tetO-hMR 
mouse strain with an α-MHC-tTA transactivator mouse strain14. Littermate wild-type, gender-
matched mice (WT) were used as controls. In some of them, after
 
pentobarbital sodium anesthesia 
(30 mg/kg), osmotic minipumps (Model 2 ML4,
 
Alza Corporation) were subcutaneously implanted 
for constant delivery of 50g/day D-Aldosterone (dissolved in 0.9% saline) over 3 weeks. Chronic 
aldosterone infusion significantly increased the plasma aldosterone concentration above control 
levels (from 278±77 [n=7] to 1374±150 [n=7] pg/ml, P<0.05). Mice were devoid of cardiac 
hypertrophy either on whole organ (heart weight-to-body weight ratio in mg/g: 5.9±0.4 [n=15], 
5.9±0.3 [n=11] and 5.3±0.4[n=6] in WT, aldosterone-treated and hMR mice, respectively, P>0.05) 
or at cellular level (membrane capacitance in pF: 201.8±6.1 [n=30], 199.6±12.7 [n=21] and 
 5 
199.0±11.0 [n=26] for isolated ventricular myocytes from WT, aldosterone-treated and hMR mice, 
respectively, P>0.05). 
Action potential recording 
Whole cell patch clamp method was used in current clamp configuration to record APs using 
solutions and protocol as described
11
. 
Spontaneous local SR Ca
2+
 release: Ca
2+ 
sparks 
Fluo-3AM loaded cells were imaged in Tyrode solution (in mmol/L: NaCl 130, NaH2PO4 0.4, 
NaHCO3 5.8, CaCl2 1, MgCl2 0.5, KCl 5.4, glucose 22, HEPES 25, insulin 0.01, pH 7.4) using a 
confocal microscope in line scan mode
11
. 
Cell lysate and SR-enriched membrane fraction (SR fraction) 
Cell lysates were prepared with homogenization buffer (in mmol/L: sucrose 300, NaF 20, 
HEPES 20, Aprotinin 5.2 10
-4
, Benzamidine 0.5, Leupeptin, 0.012, PMSF 0.1, pH 7.2) using a 
Potter-Elvehjem and spun at 2,000 g for 10 min. SR fractions were isolated by ultracentrifugation at 
40,000 g for 30 min at 4°C
17
. 
17
Protein concentration by Bradford method and binding of 
[
3
H]ryanodine to SR fractions were assessed
17
. 
Single-channel recordings 
Analysis of RyR single-channel activity was done by fusing SR vesicles into planar lipid 
bilayers using Cs
+
 as charge carrier
17
. Only bilayers containing a single channel were used. Channel 
activity was always tested for sensitivity to EGTA, added in the cis chamber at the end of each 
experiment. 
RT-PCR analysis  
Total RNA was extracted using Trizol (InVitrogen). First strand cDNA was synthesized after 
DNaseI treatment (DNAfree, Ambion) using 1 µg of total RNA, random hexamers (Amersham) and 
Superscript II reverse transcriptase (InVitrogen). Transcripts levels were analyzed in triplicate by 
real time PCR with an iCycler iQ apparatus (Bio-Rad) using a qPCR Core Kit for SYBR Green I 
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(Eurogentec) containing 500 nmol/L of specific primers (Table S1) and 3 µL of diluted template 
cDNA. Relative expression of FKBPs and RyR were normalized by the geometric average of 
relative quantities for reference genes. Serial dilutions of pooled cDNA were used in each 
experiment to assess PCR efficiency. 
Immunoblots 
Immunoblots were prepared from cell lysates using anti-FKBP12/12.6 (1:1000, Santa-Cruz 
Biotechnology Inc), anti-RyR (1:3000, Affinity Bioreagents), and anti-actin (1:20000, Sigma) 
antibodies. FKBP12/12.6-RyR interaction was assessed on SR fractions using anti-FKBP12/12.6 
(1:200) and anti-RyR (1:1000) antibodies from Affinity BioReagents. Immunoblots of RyR 
phosphorylation were performed using anti–RyR-PS2809 (1:5000) antibody from Badrilla (Leeds, 
West Yorkshire, UK) and anti–RyR-PS2815 (1:5000) antibody generously provided by Dr A.R. 
Marks (Columbia University, New York, NY). 
Statistics 
Preliminary descriptive analyses include frequencies for categorical variables and means±SD for 
continuous ones. A conditional hierarchical linear model was used (SAS/UNIX statistical software, 
SAS Institute, Cary, N.C. proc mixed) to compare continuous variables between groups to take into 
account for multiple observations per animals. The group was a fixed effect, animals were a random 
effect nested in the group and, in case of repeated measures on cells, we add a random effect for cell 
in animal. 
Data are presented as mean±SEM and compared using Student's t test (for two groups) or ANOVA 
(for more groups followed up with a post-hoc pairwise Tukey’s HSD test). Significance was 
defined at P<0.05. 
 
Results 
Aldosterone pathway increases occurrence of DADs. 
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During AP recordings, at 0.1-Hz cycle length in ventricular myocytes isolated from transgenic 
mice expressing hMR in the heart (hMR mice, Fig.1A), we observed oscillations in membrane 
potential following completion of the driven AP (Fig.1A middle). Eventually, the DAD was large 
enough to reach the threshold to trigger spontaneous AP (Fig.1A right). The occurrence of DADs 
was greatly enhanced by the activation of aldosterone pathway (Fig.1B). Ex vivo, after 48-hours 
exposure of isolated rat ventricular myocytes to 100-nmol/L aldosterone, the occurrence of DADs 
increased compared with control myocytes kept 48 hours in absence of aldosterone. Likewise in 
vivo, increases of DAD occurrence appeared after 3-week minipump infusion of aldosterone in WT 
mice or in hMR mice, as compared to untreated WT littermates. 
Modulation of Ca
2+
 sparks by aldosterone pathway.  
DADs are commonly initiated by non-electrically driven, spontaneous Ca
2+
 release from the 
SR via the RyRs
8
. We thus examined the properties of RyRs in situ, by visualizing spontaneous 
Ca
2+
 sparks that reflect brief and local Ca
2+
 release events occurring when RyRs open
18,19
. Figure 
2A shows line scan images of cells isolated from WT, aldosterone-treated and hMR mice. Either 
elevated circulating aldosterone or cardiac hMR expression resulted in ~1.6-fold increase of Ca
2+
 
spark frequency (Table S2, Fig.2B). No differences in mean values for Ca
2+
 spark amplitude 
(Fig.2C) or rise time (Fig.2D) were seen between the 3 groups. As noticed in Figure 2A, besides 
“classical” Ca2+ sparks characterized by a brief and localized increase in the fluorescence signal (a 
half time of decay ~30 ms and a diameter of ~2 m)18, we also observed the appearance of widened 
(>4 m) and long-lasting Ca2+ release events (>80 ms). A mixed-effect model revealed increases of 
both averaged Ca
2+
 spark full widths (FWHM) and durations (FDHM) at half maximal in 
aldosterone-treated and hMR mice (Table S2), which might reflect differences in population 
proportions. The distributions of FWHM and FDHM were empirically fitted to bimodal Gaussian 
functions (Fig.2E and F). The distributions of FWHM showed a prominent mode near 2.8 µm and a 
second minor mode near 4.3 m, whatever the conditions. However, the proportion of events 
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showing larger width was greater in aldosterone-treated and hMR mice compared with WT (Table 
1). Moreover, events lasting more than 50 ms were more frequent in aldosterone-treated and hMR 
mice compared with WT. Distributions of log(FDHM) were fitted by 2 Gaussian distributions with 
2 distinct peaks ~32 and 87 ms, but the frequency of long-lasting signals were larger in aldosterone-
treated and hMR mice than that observed in WT mice (Table 1). No correlation between Ca
2+
 spark 
spatio-temporal characteristics was observed. This is consistent with occurrence of three different 
populations of Ca
2+
 sparks, whose redistributions to long-lasting and larger spread area populations 
were increased by activation of the cardiac aldosterone pathway. 
While the effects of aldosterone in vivo are presumably due to its direct cardiomyocyte effect, 
aldosterone might cause release of second messengers from non-cardiac cells that can affect Ca
2+
 
sparks. To exclude this possibility we examined the properties of spontaneous Ca
2+
 sparks of 
isolated rat ventricular myocytes kept 48 hours with or without 100-nmol/L aldosterone. Three 
different populations of Ca
2+
 sparks were also observed (Fig.3): the normal Ca
2+
 sparks are narrow 
and brief (Fig.3A); the second population of Ca
2+
 sparks is substantially wider in space, but only 
slightly longer in duration (Fig.3B); the third population of Ca
2+
 sparks has the same width as the 
normal but is very much longer in duration (Fig.3C). Analysis of the distributions of FWHM 
(Fig.3D) and FDHM (Fig.3E) showed that ex vivo aldosterone exposure increases the occurrence of 
both wider and longer populations (Tables 1 and S2). In addition, we observed a 1.9-fold increase in 
Ca
2+
 spark frequency (Table S2, Fig.3F), whereas mean Ca
2+
 spark amplitude (Fig.3G) and rise 
time (Fig.3H) were not affected. Co-incubation with a specific MR antagonist, RU28318
11,12,13
, 
prevented aldosterone-induced changes in Ca
2+
 spark properties (Fig.3). 
Aldosterone effects on Ca
2+
 sparks might arise from modulation of RyR intrinsic properties. 
The open probability of RyRs is influenced by the amount of Ca
2+
 stored in the SR
20
. A 
potential increase of SR Ca
2+
 load by aldosterone could therefore underlie the observed effects on 
Ca
2+
 sparks. SR Ca
2+
 load was estimated by rapid caffeine application (10 mmol/L) in the same 
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intact cells used for Ca
2+
 sparks
11,21
. No difference (P>0.05) was observed in hMR mice (peak F/F0: 
4.0±0.1, n=56) and in aldosterone-treated mice (3.8±0.2, n=43) compared to WT (4.1±0.1, n=29). 
As well, no difference in the caffeine-evoked Ca
2+
 transients was noticed after ex vivo aldosterone 
exposure (3.7±0.2 and 4.0±0.2 in control [n=13] and aldosterone treated myocytes [n=13], 
respectively, P>0.05). These results are consistent with the absence of alteration in Ca
2+
 spark 
amplitude and suggest that aldosterone does not modulate RyR activity (and hence, Ca
2+
 sparks), by 
altering SR content. 
Ca
2+
 sparks result from the opening of clusters of RyRs, thus, increased Ca
2+
 spark frequency 
might result from increased RyR expression. Immunoblot analysis of cell lysates showed similar 
RyR amounts (after normalization against control, ratios of RyR to actin levels were: 1±0.3 [n=8], 
0.95±0.3 [n=4] and 0.82±0.3 [n=4] in WT, WT+Aldo and hMR mice, respectively, P>0.05; and 
1±0.2 [n=8], 0.94±0.2 [n=4] in rat ventricular myocytes kept 48 hours without and with aldosterone, 
respectively, P>0.05). RyR expression of isolated rat cardiomyocytes kept 48 hours with or without 
aldosterone, examined by [
3
H]ryanodine binding to SR fractions, indicated unchanged high-affinity 
binding site for ryanodine (Kd values in nmol/L: 1.5±0.2 and 1.8±0.4 after 48 hours incubation with 
[n=6] and without aldosterone [n=6], respectively; P>0.05) and similar expression levels of RyR 
after aldosterone exposure (maximal receptor density: 0.24±0.04and 0.29±0.03 pmol/mg of protein, 
respectively, P>0.05). 
These results showed that activation of the aldosterone pathway in cardiac myocytes alters 
Ca
2+
 spark properties without modifying SR Ca
2+
 content or RyR expression. Therefore, 
aldosterone modulation of Ca
2+
 sparks might arise from changes in the intrinsic activity of the RyR 
complex. As an index, we fused SR fractions from control and aldosterone-treated rat 
cardiomyocytes into planar lipid bilayers to record single channel activity of RyR. Besides classical 
bimodal gating
20
, characterized by sequences of flickering openings with low (Fig.4A) and high 
(Fig.4B) open probability, a clearly distinct long and relatively stable openings with similar unitary 
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current amplitude were observed (Fig.4C). Measurements from holding potentials –35 to +35 mV 
showed that current-voltage relationships had similar conductance of 639, 632 and 640 pS (for 
Fig.4A, B and C, respectively). These results suggested that all recorded channel activity 
corresponded to RyRs, however, although the burst and long-lasting modes were observed in 
channels with and without aldosterone treatment, these modes occurred more frequently after 
aldosterone exposure (Fig.4D). 
FKBP12/12.6 downregulation by mineralocorticoid pathway. 
Taken together, our results indicate that aldosterone through MR increases the likelihood that 
RyRs open abnormally during diastole, which might reflect changes in intrinsic properties of the 
RyR. Activity of RyR is tightly regulated by several accessory proteins that form a macromolecular 
signaling complex with RyR
15,16
. Among these ancillary proteins, FK506-binding proteins 
(FKBP12 and 12.6) have been involved in the incidence of subsets of cardiac Ca
2+
 sparks with 
longer duration and wider spatial spread, along with increased frequency
21-23
. Therefore, we 
assessed the expression of FKBP12/12.6 protein levels. Compared to the respective controls, 
immunoblot analysis of cell lysates showed decreases in the amount of FKBP12/12.6 relative to 
actin levels after in or ex vivo aldosterone exposure and in hMR mice (Fig.5A). The RyR-
FKBP12/12.6 association was indirectly assessed by measuring the ratio of FKBP12/12.6 to RyR 
detected in the SR fractions
24-26
. Immunoblot analysis indicates that the relative amounts of 
FKBP12/12.6 to RyR are decreased in the heart of hMR mice or WT mice treated with aldosterone 
compared to control WT (Fig.5B). Because RyR phosphorylation could influence FKBP12/12.6-
RyR association
15,16
, we examined RyR phosphorylation status following activation of the 
mineralocorticoid pathway. RyR contains multiple phosphorylation sites including RyR-Ser2815 
(phosphorylated by CaMKII)
27
 and RyR-Ser2809 (phosphorylated by both CaMKII and PKA)
28
. 
Using 2 different phospho-specific antibodies (RyR-PS2815 and RyR-PS2809) on SR fractions, we 
observed no difference in the ratio of phosphorylated RyR to total RyR among groups (Fig.5C). To 
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distinguish FKBP12 versus FKBP12.6 expression, real-time quantitative PCR was used to assess 
mRNA levels with specific primers. At mRNA level, a decreased expression of both FKBP12 and 
12.6 was observed in the 3 models studied compared to respective controls (Fig.5D), whereas 
mRNA levels of RyR were not altered (data not shown). 
 
Discussion 
In summary, long-term aldosterone exposure ex or in vivo, or cardiac hMR expression in 
transgenic mice, increases the occurrence of DADs, in line with abnormal diastolic openings of 
RyR, which are associated with down-regulation of FKBP12 and 12.6. While the link might be 
circumstantial, several lines of evidence suggest that over-stimulation of the cardiac 
mineralocorticoid pathway may be a major upstream factor for aberrant Ca
2+
 release during 
diastole, contributing to cardiac arrhythmia in HF. 
Numerous experimental and clinical studies indicate that the aldosterone pathway participates 
in cardiac alterations associated with hypertension, HF, diabetes and other pathologies
1,3-6,12,14
. 
Notably, inappropriate activation of cardiac MR is a likely participant in the development of poor 
outcomes for patients with HF, especially those associated with cardiac arrhythmia
5,6
. Interestingly, 
hMR mice presented high mortality and increased occurrence of arrhythmia
14
. One of the possible 
cellular mechanisms for those arrhythmias is triggered activity caused by EADs and DADs, both of 
which are commonly associated with intracellular Ca
2+
mishandling. We previously reported that 
along with AP lengthening, EADs occur in hMR mice
14
. The incidence of EADs was (in %) 1, 11 
and 14 in ventricular myocytes isolated from WT, aldosterone-treated and hMR littermate mice, 
respectively. In addition, we observed that 10% of rat ventricular myocytes incubated 48 hours with 
aldosterone presented EADs, whereas none was observed in control. Here, we found that the 
incidence of DAD is approximately 2-fold higher, thus constituting a substantial mechanism for 
aldosterone pathway-induced arrhythmias. 
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Whereas many Ca
2+
-handling proteins are involved in DAD-related arrhythmias, abnormal 
opening of the RyR during diastole is an essential
 
component
7,8
. We show here that aldosterone 
pathway increased the occurrence, and changed the spatio-temporal properties, of spontaneous Ca
2+
 
sparks. Similar alterations were found either ex vivo by incubating adult cardiac myocytes with 
aldosterone, or in vivo in mouse hearts after chronic delivery of aldosterone or hMR expression. 
These consistent findings suggest that a direct activation of cardiac MR by aldosterone modifies 
Ca
2+
 spark phenotype, independently of other compensatory changes in vivo. Indeed, ex vivo 
aldosterone effects are prevented by a specific MR antagonist. In addition, hMR mice have 
increased aldosterone receptor activity, presumably due to physiologic aldosterone levels, as 
assessed by prevention of phenotype effects with MR antagonist
14
. Moreover, MR antagonists also 
prevented other aldosterone-induced cardiac effects
10,11,13
. 
Although we cannot exclude that the effects might be secondary to other modulations in 
myocyte Ca
2+
 handling, several lines of evidence suggest that activation of MR by aldosterone 
directly affects RyR activity. The increase in Ca
2+
 spark frequency is not due to an increase in SR 
Ca
2+
 load but rather might reflect a modulation of the intrinsic properties of the RyR complex. 
Besides the increase in Ca
2+
 spark frequency, we observed a redistribution of Ca
2+
 sparks to long-
lasting and broader populations. These “abnormal” Ca2+ sparks were also seen in control conditions, 
but at much lower frequency. Others have also found Ca
2+
 sparks that are longer or wider than the 
“classic” Ca2+ sparks in control conditions18,21,29-31. The incidence of wide (>2 m) and long (60-80 
ms) Ca
2+
 sparks is increased in left ventricular hypertrophy in the dog without alteration in Ca
2+
 
spark amplitude
32
. Here, aldosterone exposure or cardiac hMR expression increased the proportions 
of long and wide Ca
2+
 sparks from 4-6% to 9-19% and from 4-6% to 16-30%, respectively, 
constituting a substantial effect. This indicates that aldosterone does not induce a new kind of Ca
2+
 
sparks, but modifies the activity of functional release units. 
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Along with this alteration, we observed a significant down-regulation of FKBP12 and 12.6 
expressions without variation in the density of RyRs. Even if other alterations may contribute to the 
observed modifications of Ca
2+
 sparks characteristics, no other RyR-associated proteins have been 
shown to induce similar modulations as FKBP does. The FKBP12/12.6 binding to RyRs modulates 
the Ca
2+
-flux properties of the channel
 
complex; in particular, it regulates RyR open probability and 
stability at rest
20,33,34
 (but see also
35
). FKBP12.6 removal by pharmacological approaches
22,36,37
 or 
transgenic animal models
23
, and conversely adenoviral short-term FKBP12.6 overexpression
21,38
 
modulated Ca
2+
 sparks frequency and occurrence of longer and wider Ca
2+
 sparks, in a similar 
manner to what we observed here. We showed that activation of cardiac aldosterone pathway 
produced a decreased expression of FKBPs. In addition, we have assessed the RyR-FKBP12/12.6 
association in hMR transgenic and WT mice treated with aldosterone. Our results suggest that in 
mouse hearts, activation of the aldosterone pathway results in substantially reduced RyR-
FKBP12/12.6 interaction that could be the cause of the observed RyR-mediated Ca
2+
 leak. These 
effects are not associated with alteration of RyR phosphorylation status but might reflect a genomic 
regulation of FKBP12/12.6 by cardiac aldosterone pathway, as evidenced by the decrease in mRNA 
levels of FKBP12 and 12.6. Now, partial loss of FKBP12.6 from RyR in HF has been shown to 
cause diastolic Ca
2+
 leak that may result in higher propensity of DADs and consequent triggered 
arrhythmias
15,16,23,39-45
. In addition, myocardial FKBP12.6 overexpression prevents triggered 
arrhythmias in normal hearts, probably by reducing diastolic SR Ca
2+
 leakage
46
. Beyond the 
controversial hypothesis for excess RyR activity due to hyperphosphorylation reducing RyR affinity 
for FKBP12.6
47
, most of the studies show a reduction of FKBP protein level in HF
23,39-45
. Thus, we 
suggest that activation of the aldosterone pathway might be an essential step in the cascade of 
molecular events leading to FKBP deficiency that causes RyR Ca
2+
 leakage, and trigger malignant 
cardiac arrhythmias in HF. 
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Taken together, our findings may partly explain why the use of MR antagonists on top of 
optimal medical therapy is associated with improved survival, and fewer sudden cardiac deaths in 
patients. 
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Figure Legends. 
Figure 1. Activation of aldosterone pathway increases the occurrence of delayed after-
depolarizations (DADs). A. Representative action potentials recorded from the same hMR 
cardiomyocyte, elicited at 0.1 Hz, showing the appearance of spontaneous depolarization (middle, 
DAD indicated by the arrows) and triggering spontaneous AP (right). B. Bar graph plots number of 
cells presenting at least 1 DAD in rat ventricular myocytes incubated 48 hours with or without 100-
nmol/L aldosterone and in ventricular myocytes isolated from WT, aldosterone-treated WT and 
hMR littermate mice. n is the total cell number. * P<0.05. 
Figure 2. Change of the spatio-temporal properties of Ca
2+
 sparks induced by 
mineralocorticoid in vivo. A. Sample line-scan fluorescence images record from cells isolated from 
wild-type (WT, top), aldosterone-treated (WT+Aldo, middle) and hMR mice (bottom). B through 
D, Comparison of the frequency of occurrence, amplitude (F/F0), and rise time of Ca
2+
 sparks at rest 
in myocytes from WT (red open bars), WT+Aldo, (light blue bars) and hMR mice (blue bars). In B, 
n is the cell number, whereas in C and D it is the number of Ca
2+
 sparks. * P<0.05. Probability 
Density function (PDf) of Ca
2+
 spark widths (E) and durations (F) at half maximal amplitude in 
WT, WT+Aldo, and hMR mice. Curves represent mixed Gaussians fitted to the histograms. In F, 
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analyses were conducted on log(FDHM) and corresponding results are presented after back 
transformation. 
Figure 3. Ex vivo aldosterone exposure promotes the occurrence of wide-spread and long-
lasting Ca
2+
 sparks. A to C. Representative spark images and spatio-temporal profiles from a 48-
hour aldosterone-treated cell showing that spontaneous Ca
2+ 
sparks can be: short (A), large (B) or 
long (C). The distance along the cell is represented vertically, and the time is represented 
horizontally. D and E. PDf of FWHM and FDHM after 48 hours incubation under control (cont, red 
open bars), 100-nmol/L aldosterone without (Aldo; blue bars) and with 10-mol/L RU28318 
(Aldo+RU; blue open bars) conditions. Histograms were fitted by the sum of 2 Gaussian 
distributions. F to H. Bar graphs of mean ± SEM values for Ca
2+
 spark frequency (F), amplitude 
(F/F0, G), and rise time (H). In F, n is the cell number whereas in G and H it is the number of Ca
2+
 
sparks. ** P<0.005. 
Figure 4. Single RyR channels reconstituted in lipid bilayers display three different kinetic 
behaviors: (A) short, (B) burst and (C) long openings. Each panel shows representative examples 
of single channel behaviors of RyR reconstituted from the same SR-enriched membrane fraction of 
rat ventricular myocytes incubated 48 hours in the presence of aldosterone: (top) 2-min and 500-ms 
section of the recording on an expanded time scale of single-channel traces recorded at +25 mV 
with channel openings (o) in the upward direction; (bottom) Current-voltage relationship of the 
corresponding incorporated RyR. D. Bar graphs plots the percentage of the occurrence of modal 
behaviors of reconstituted RyR channels from SR fractions of cells kept 48 hours with (Aldo, gray 
bars, n=15) and without aldosterone (cont, open bars, n=11). ** P<0.005. 
Figure 5. Down regulation of FKBP12 and 12.6 expressions after activation of cardiac 
aldosterone pathway. A to C. Representative immunoblots and quantification of (A) FKBP12/12.6 
protein levels in cardiac cell lysates (normalized to the corresponding actin level and normalized to 
respective controls), (B) FKBP12/12.6 and RyR content in SR-enriched membrane fractions (the 
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cumulative data presented are derived from four different heart preparations, each immunoblotted 
four times, and are illustrated after normalization against the WT, non-treated sample) and (C) 
Pooled data represent ratios of RyR-P2815 and RyR-P2809 to RyR from SR-enriched membrane 
fractions normalized to respective controls from WT (open bars), aldosterone-treated WT 
(WT+Aldo, hatched bar) and hMR (closed bars) mice; and in rat ventricular myocytes incubated 48 
hours with (+Aldo, closed bar) or without (cont, open bar) 100-nmol/L aldosterone. D. Real time 
RT-PCR analysis of the cardiac tissue content of FKBP12 and 12.6. 2-microglobulin, GAPDH, 
HPRT and UBC were used as reference genes and the relative mRNA levels were normalized to the 
geometric average of relative quantities for reference genes. * P<0.05. 
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Table 1. Mean (), standard deviation (), proportion (p in %) and coefficient of determination (r2) 
of Gaussian fits to Ca
2+
 spark parameters. 
 
 
                                              FWHM (m) FDHM (ms)
   p1   p2 r
2
   p1   p2 r
2
 
Aldo in vivo               
WT 2.79 0.91 93.5 4.32 0.60 6.5 0.98 30.9 5.6 96.0 85.2 23.9 4.0 0.98 
WT+Aldo 2.80 0.84 83.8 4.30 1.20 16.2 0.99 32.4 5.9 91.0 87.6 30.2 9.0 0.99 
hMR 2.78 0.71 70.2 4.33 1.15 28.8 0.99 33.4 5.9 81.6 89.4 27.9 18.4 0.99 
Aldo ex vivo               
control 2.61 0.89 94.5 4.85 0.71 5.5 0.99 33.7 6.3 94.0 103.0 41.1 6.0 0.99 
Aldo 2.62 0.91 72.0 4.60 1.25 28.0 0.99 33.5 6.3 81.7 106.0 50.3 18.3 0.99 
Aldo+RU 2.54 0.78 95.8 4.53 0.70 4.2 0.99 33.7 5.7 95.7 105.3 35.2 4.3 0.99 
 
FWHM and FDHM: Full width and duration at half maximal amplitude. 
 
 
